# A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function

> **NCT01006057** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 32 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** insulin degludec
- **DRUG:** insulin degludec
- **DRUG:** insulin degludec
- **DRUG:** insulin degludec
- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT01006057
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01006057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01006057, "A Trial Investigating the NN1250 Concentration-time Curve in Subjects With Various Degrees of Renal Impairment and in Subjects With Normal Renal Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01006057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*